Cradle
Provides generative AI software for engineering proteins and optimizing cellular factories.
What they do
Cradle develops generative AI tools that assist biologists in designing improved proteins and enzymes. The software predicts how amino acid sequences affect properties like stability and activity, helping industrial biotech and pharmaceutical teams reduce the number of wet-lab experiments required.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Delft, Netherlands
- Region
- Europe
- Founded
- 2022
- Total funding
- $33M raised
Notable investors: Index Ventures, Kindred Capital.